Tiziana Life Sciences is a biotechnology company that is focused on the discovery and development of molecules to treat unmet medical needs in oncology and immunology. Co.'s main product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody (mAb) in clinical development. MAbs represent a single pure antibody produced by single clones and are a class of human therapeutics for treating cancers and autoimmune diseases. Co.'s main product candidate in oncology is Milciclib (TZLS-201), which is an orally bioavailable, small molecule spectrum inhibitor of cyclin-dependent kinases, and Src family kinases. The TLSA average annual return since 2018 is shown above.
The Average Annual Return on the TLSA average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TLSA average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TLSA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|